Research Protocol
Médecins Sans Frontières (MSF)-OCBA, Ugandan Ministry of Health

“Effectiveness of nutritional supplementation (RUTF and multi micronutrient) in preventing malnutrition in children 6-59 months with infection (malaria, pneumonia, diarrhoea), a randomized controlled trial in Kaabong Hospital. Karamoja, Uganda”

Final Version
Study Sponsors: Médecins Sans Frontières (MSF)-OCBA
December 2010
## 1. Investigators and institutional affiliations

Key investigators are listed below.

<table>
<thead>
<tr>
<th>Investigator Role</th>
<th>Name</th>
<th>Institution</th>
<th>Address</th>
<th>Contact Information</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study Principal Investigator</strong></td>
<td>Núria Salse Ubach, Nutrition,</td>
<td>Médicins Sans Frontières Barcelona</td>
<td>Nou de la Rambla, 26 (08001) Barcelona</td>
<td>Tel.: +34 93 304 61 88 <a href="mailto:nuria.salse@barcelona.msf.org">nuria.salse@barcelona.msf.org</a></td>
</tr>
<tr>
<td>Co-Investigator</td>
<td>Saskia van der Kam,</td>
<td>Médicins Sans Frontières Amsterdam</td>
<td>Plantage Middenlaan 14</td>
<td>Tel: 00 31 20 5208 978 <a href="mailto:Saskia.vd.kam@amsterdam.msf.org">Saskia.vd.kam@amsterdam.msf.org</a></td>
</tr>
<tr>
<td>Co-Investigator</td>
<td>Swarthout Todd</td>
<td>Médicins Sans Frontières Amsterdam</td>
<td>Plantage Middenlaan 14</td>
<td>Tel: 00 31 (0)20 52 08 009 <a href="mailto:todd.swarthout@amsterdam.msf.org">todd.swarthout@amsterdam.msf.org</a></td>
</tr>
<tr>
<td>Co-Investigator</td>
<td>Akiko Matsumoto</td>
<td>Médicins Sans Frontières</td>
<td>Kaabong, Karamoja (Uganda)</td>
<td>Tel. +256 (0) 775 963 703 <a href="mailto:msfe-karamoja@barcelona.msf.org">msfe-karamoja@barcelona.msf.org</a></td>
</tr>
<tr>
<td>Co-Investigator</td>
<td>Dr James Kisambu, District Health Officer</td>
<td>Médicins Sans Frontières</td>
<td>Kaabong, Karamoja district, Uganda</td>
<td>Tel. +256 (0) 772 927 164 <a href="mailto:drkisambu@yahoo.com">drkisambu@yahoo.com</a></td>
</tr>
<tr>
<td>Co-Investigator</td>
<td>Grace Otelu Edyegu</td>
<td>Médicins Sans Frontières</td>
<td>Kaabong, Karamoja (Uganda)</td>
<td>Tel. +256 (0) 772 969 380 <a href="mailto:ograceedyegu@yahoo.com">ograceedyegu@yahoo.com</a></td>
</tr>
<tr>
<td>Co-Investigator</td>
<td>Veronique De Clerck, Medical Coordinator</td>
<td>Médicins Sans Frontières</td>
<td>Kampala, Uganda</td>
<td>Tel.: +256 (0) 782 917 599 <a href="mailto:Msfe-kampala-medco@barcelona.msf.org">Msfe-kampala-medco@barcelona.msf.org</a></td>
</tr>
<tr>
<td>Co-Investigator</td>
<td>Cristian Casademont</td>
<td>Médicins Sans Frontières</td>
<td>Nou de la Rambla, 26 (08001) Barcelona</td>
<td>Tel.: + 34 93 304 61 67 <a href="mailto:cristian.casademont@barcelona.msf.org">cristian.casademont@barcelona.msf.org</a></td>
</tr>
<tr>
<td>Co-Investigator</td>
<td>Dr. Pedro Pablo Palma, Medical Director</td>
<td>Médicins Sans Frontières</td>
<td>Nou de la Rambla, 26 (08001) Barcelona</td>
<td>Tel.: +34 93 304 62 12 <a href="mailto:PedroPablo.PALMA@barcelona.msf.org">PedroPablo.PALMA@barcelona.msf.org</a></td>
</tr>
<tr>
<td>Statistician</td>
<td>Dr. Stephanie Roll</td>
<td>Institute for Social Medicine,</td>
<td>Epidemiology and Health Economics Charité University Medical Center</td>
<td>Tel.: +49 30 450 529023 <a href="mailto:stephanie.roll@charite.de">stephanie.roll@charite.de</a></td>
</tr>
<tr>
<td>Technical Advisor</td>
<td>Paul Roddy, Epidemiologist,</td>
<td>Médicins Sans Frontières</td>
<td>Nou de la Rambla, 26 (08001) Barcelona</td>
<td>Tel.: + 34 93 304 61 62 <a href="mailto:Paul.RODDY@barcelona.msf.org">Paul.RODDY@barcelona.msf.org</a></td>
</tr>
</tbody>
</table>
ACKNOWLEDGMENTS:
MSF-OCA wants to thank the team of MSF-OCA for developing and sharing the protocol
Saskia VD Kam: nutritionist Médecins Sans Frontières, Amsterdam
Todd Swarthout: Epidemiologist Médecins Sans Frontières, Amsterdam
Leslie Shanks: Medical Director Médecins Sans Frontières Amsterdam
Dr. Nma M. Jiya, Paediatrician, UDUTH, Sokoto, Nigeria
Michael Boele-van Hensbroek: Paediatrician AMC
Stephanie Roll: Bio-statistician, Institute for Social medicine, Epidemiology and Health Economics, Charité University Medical Center, Berlin, Germany
Peter Tinneemann: Scientist, Institute for Social medicine, Epidemiology and Health Economics, Charité University Medical Centre, Berlin, Germany

Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAH</td>
<td>Action Against Hunger</td>
</tr>
<tr>
<td>AE</td>
<td>Adverse event</td>
</tr>
<tr>
<td>AR</td>
<td>Adverse reaction</td>
</tr>
<tr>
<td>DOTS</td>
<td>Directly observed treatment</td>
</tr>
<tr>
<td>DRC</td>
<td>Democratic Republic of Congo</td>
</tr>
<tr>
<td>EDTA</td>
<td>Ethylene diamine tetra-acetate</td>
</tr>
<tr>
<td>FRC</td>
<td>Field research coordinator</td>
</tr>
<tr>
<td>GAM</td>
<td>Global acute malnutrition</td>
</tr>
<tr>
<td>HQ</td>
<td>Headquarters</td>
</tr>
<tr>
<td>ITT</td>
<td>Intention to treat</td>
</tr>
<tr>
<td>LGA</td>
<td>Local Government Authority</td>
</tr>
<tr>
<td>LRTI</td>
<td>Lower respiratory tract infection</td>
</tr>
<tr>
<td>MAM</td>
<td>Moderate acute malnutrition</td>
</tr>
<tr>
<td>MCH</td>
<td>Mother and child health</td>
</tr>
<tr>
<td>MoH</td>
<td>Ministry of Health</td>
</tr>
<tr>
<td>MMN</td>
<td>Multi-micronutrient</td>
</tr>
<tr>
<td>MNP</td>
<td>Multi-micronutrient powder</td>
</tr>
<tr>
<td>MSF-OCA</td>
<td>Médecins Sans Frontières – Operational Centre Amsterdam</td>
</tr>
<tr>
<td>MUAC</td>
<td>Mid upper arm circumference</td>
</tr>
<tr>
<td>NNO</td>
<td>Negative nutritional outcome</td>
</tr>
<tr>
<td>OPD</td>
<td>Outpatient department</td>
</tr>
<tr>
<td>PI</td>
<td>Primary investigator</td>
</tr>
<tr>
<td>PP</td>
<td>Per protocol</td>
</tr>
<tr>
<td>QC</td>
<td>Quality control</td>
</tr>
<tr>
<td>RDT</td>
<td>Rapid diagnostic test</td>
</tr>
<tr>
<td>RDI</td>
<td>Recommended daily intake</td>
</tr>
<tr>
<td>RNI</td>
<td>Recommended nutritional intake</td>
</tr>
<tr>
<td>RR</td>
<td>Risk ratio</td>
</tr>
<tr>
<td>RUF</td>
<td>Ready to use food</td>
</tr>
<tr>
<td>RUTF</td>
<td>Ready to use therapeutic food</td>
</tr>
<tr>
<td>SAE</td>
<td>Serious adverse event</td>
</tr>
<tr>
<td>SAM</td>
<td>Severe acute malnutrition</td>
</tr>
<tr>
<td>SAP</td>
<td>Statistical analysis plan</td>
</tr>
<tr>
<td>SAR</td>
<td>Serious adverse reaction</td>
</tr>
<tr>
<td>TFP</td>
<td>Therapeutic feeding program</td>
</tr>
<tr>
<td>U5MR</td>
<td>Under-five mortality rate</td>
</tr>
</tbody>
</table>
Glossary

Not malnourished  \( W/H \geq -2 \text{ z-scores} \)

Moderate acute malnutrition (MAM)  \( W/H < -2 \text{ and } \geq -3 \text{ z-scores} \)
\( \text{MUAC } \geq 115 \text{mm to } < 125 \text{mm} \)

Severe acute malnutrition (SAM)  \( W/H < -3 \text{ z-scores or} \)
\( \text{MUAC } < 115 \text{ or} \)
\( \text{Bilateral oedema} \)

Acute malnutrition:  Includes either SAM or MAM

Global acute malnutrition (GAM)  \( W/H < -2 \text{ z-scores or} \)
\( \text{MUAC } < 125 \text{ or} \)
\( \text{Bilateral oedema} \)

Rate of weight change  Grams weight change / kg body weight at inclusion / days follow-up
Table of contents
1. Investigators and institutional affiliations ................................................................. 2
Abbreviations .................................................................................................................... 3
Glossary .............................................................................................................................. 4
Table of contents .............................................................................................................. 5
EXECUTIVE SUMMARY ................................................................................................... 6
1. INTRODUCTION ......................................................................................................... 8
1.1 Background .............................................................................................................. 8
1.2 The inter-relationship between infection and malnutrition .................................. 9
1.3 Effect of supplementation ..................................................................................... 10
1.3.1 Supplementation to prevent malnutrition ....................................................... 10
1.3.2 Supplementation and reduced risk of disease ................................................... 10
1.4 Supplements .......................................................................................................... 11
1.4.1 Ready to Use Therapeutic Food ...................................................................... 11
1.4.2 Multi-Micronutrient powder ........................................................................... 11
1.5 Rationale for the study ........................................................................................... 11
2. STUDY OBJECTIVES .................................................................................................. 13
3. STUDY DESIGN .......................................................................................................... 14
4. STUDY SITE ................................................................................................................ 14
4.1 Number of Participants ......................................................................................... 14
4.2 Inclusion criteria ..................................................................................................... 14
4.3 Exclusion criteria ..................................................................................................... 14
5. PARTICIPANT SELECTION AND ENROLMENT ......................................................... 15
5.1 Identifying participants ......................................................................................... 15
5.2 Consenting participants ....................................................................................... 15
5.3 Screening for eligibility ....................................................................................... 15
5.4 Ineligible and non-recruited participants ............................................................ 15
6. RANDOMISATION ..................................................................................................... 15
6.1 Randomisation ....................................................................................................... 15
6.2 Blinding .................................................................................................................. 16
6.3 Treatment allocation ............................................................................................. 16
7. NUTRITIONAL SUPPLEMENTATION ....................................................................... 16
7.1 RUTF (Plumpynut®) ............................................................................................. 16
7.2 MNP (MilaMe®) .................................................................................................... 16
7.3 Control group ......................................................................................................... 16
8. CLINICAL PROCEDURES AND METHODOLOGY ................................................. 17
8.1 Study clinic procedures at day of inclusion (day-0) ................................................. 17
8.2 Follow-up schedule ............................................................................................... 17
8.3 Measuring malnutrition ....................................................................................... 18
8.3.1 Weight ............................................................................................................... 18
8.3.2 Height ............................................................................................................... 18
8.3.3 MUAC .............................................................................................................. 19
8.4 Three study diseases ............................................................................................ 19
8.5 Compliance .......................................................................................................... 19
8.6 Emergency unblinding procedures ....................................................................... 19
8.7 Withdrawal procedures ......................................................................................... 19
8.8 Endpoints .............................................................................................................. 20
8.8.1 Primary endpoint ............................................................................................. 20
8.8.2 Secondary endpoints ....................................................................................... 20
8.9 Data collection ....................................................................................................... 20
9. DATA ANALYSIS ...................................................................................................... 20
9.1 Sample size ............................................................................................................ 21
9.2 Populations for analysis ....................................................................................... 21
9.3 Descriptive Analyses ........................................................................................... 22
9.3.1 Primary analysis of the primary endpoint ....................................................... 22
9.3.2 Secondary analysis of the primary endpoint .................................................... 22
9.3.3 Analyses of secondary endpoints ................................................................... 23
9.3.4 Pooled analysis ............................................................................................... 23
9.3.5 Statistical analysis plan and software ............................................................... 24
10. QUALITY CONTROL .................................................................................................. 24
10.1 Coordination ......................................................................................................... 24
10.2 Diagnostics ............................................................................................................ 24
10.3 Staff, Training, and Supervision ......................................................................... 24
11. ETHICAL CONSIDERATIONS ............................................................................... 24
11.1 Treatment of participants .................................................................................... 24
11.2 Cooperation with national and local partners .................................................... 25
11.3 Benefits to the community .................................................................................. 25
11.4 Feedback of results ............................................................................................. 26
11.5 Potential risks ....................................................................................................... 26
11.6 Adverse events .................................................................................................... 26
11.7 Interim analysis and Data and Safety Monitoring Board ..................................... 26
12. STUDY INVESTIGATORS AND THEIR ROLES ....................................................... 27
13. REFERENCES ............................................................................................................. 29
EXECUTIVE SUMMARY

Title:
“Effectiveness of nutritional supplementation (RUTF and multi micronutrient) in preventing malnutrition in children 6-59 months with infection (malaria, pneumonia, diarrhoea), a randomized controlled trial in Kaabong Hospital. Karamoja, Uganda”

Status: final version for submission to Ethical Review Board.
Expected Start date of the field research: September 2010.
Location: Paediatric OPD Kaabong Hospital. Karamoja, Uganda.

Objectives:
Overall objective: To determine the effectiveness of 14 days supplementation with Ready to use therapeutic Food (RUTF) or micronutrients alone concurrently with treatment for diarrhoea, malaria or lower respiratory tract infection (LRTI) in reducing risk of malnutrition and disease.

1. Primary aim: Effectiveness of supplementation with RUTF concurrently with treatment for diarrhoea, malaria or LRTI in reducing incidence of malnutrition
2. Secondary aims:
   a. Effectiveness of supplementation with a multi-micronutrient powder (MNP) concurrently with treatment for diarrhoea, malaria or LRTI in reducing incidence of malnutrition
   b. Effectiveness of supplementation with RUTF or MNP on reduction of frequency of diarrhoea, malaria or LRTI
   c. Explore effectiveness of the supplements in reducing malnutrition and illness in young children and breastfed children

Participant population
Children of 6 months to 59 months of age presenting at the OPD with diarrhoea, malaria or LRTI.

Inclusion criteria
6 to 59 months of age.
Non-acutely malnourished children.
Diagnosis of malaria and/or diarrhoea and/or LRTI.
Intention to remain in area for the duration of the 6 month follow-up.
Lives within approximately 60 minutes walking distance from the clinic.
Informed consent from a guardian.

Exclusion criteria
Child is exclusively breastfeeding.
Acute malnourishment of child.
Presence of ‘General Danger Signs’.
Presence of severe disease (incl. severe malaria, severe LRTI, severe diarrhoea).
Need of hospitalisation for any reason.
Known history of allergy to the nutritional supplementation
Sibling already enrolled in the study
Summary of study design

This is a randomized controlled trial with three study groups each with 734 participants.

Children participating in this study will be randomised to one of three study groups to:
A) Receive 14 days of RUTF supplementation with standard care and treatment
B) Receive 14 days of Multi-micronutrient powder (MNP) supplementation with standard care and treatment
C) Be included in a control group with standard care and treatment but not receiving nutritional supplementation

Individual follow-up will be 6 months. During this time, children included in the RUTF or MNP group will receive 14 days nutritional supplement, every time diagnosed with at least one of the three study diseases, not exceeding more than 14 days supplementation in any 28 day period. Children randomly assigned to the control group will receive equivalent care and follow-up as children receiving supplementation. The only difference is that they will not receive a nutritional supplement. Current clinical practice does not include nutritional supplement.

At recruitment written consent of the guardian is obtained. Baseline information will be collected and medical examination will be performed.
After 14 days and 28 days, and thereafter every month, the participant will be weighed and measured, medically checked and questioned about illness.

Accrual Goals
To have baseline, monthly and end data of weight and morbidity from at least 660 participants per group.

Progress to date
- The protocol is written including the tools and questionnaires.
- Ethical review is sought with MSF and Uganda ethical review committee.
- The RUTF and micronutrients are available.
- The field investigator is being recruited.
- Foreseen start date of preparation in the field: 1st October 2010.
- Start date of recruitment: October 2010.

Study Sponsors: Médecins Sans Frontières / Operational Centre Barcelona-Athens /MSF-OCBA
“Effectiveness of nutritional supplementation (RUTF and multi micronutrient) in preventing malnutrition in children 6-59 months with infection (malaria, pneumonia, diarrhoea), a randomized controlled trial in Kaabong Hospital. Karamoja, Uganda”

1. INTRODUCTION

1.1 Background

The global burden of malnutrition is staggering, with an estimated 10% prevalence of moderate acute malnutrition (55 million children) and 3.5% severe acute malnutrition (19 million children). [1] These malnourished children have a higher risk of mortality, ranging from a 3-fold increased risk for the moderately malnourished to a nearly 10-fold increase for the severely malnourished.

In sub-Saharan Africa malnutrition occurs predominantly in children under 3 years of age and is prevalent throughout the year. In many settings food security is often limited and the burden of disease debilitating for families and communities. Though difficult to quantify the risk of poor outcome that malnutrition adds to children who are ill, nutritional supplementation is considered critically important as a means to improve nutritional state and chances of successful convalescence.

An study done by MSF-OCA in Sokoto State, northwest Nigeria [Data not published], a 2009 survey performed by Médecins Sans Frontières before the hunger season showed a 14.8% prevalence of global acute malnutrition (GAM), and 4.9% severe acute malnutrition (SAM). The prevalence of stunting, a sign of chronic malnutrition, was 57% and there was an under five mortality rate (U5MR) of 1.67/10,000/day.

In the same study, among 789 children, 51% reported having an illness at some time during the previous 14 days. Normally this percentage is approximately 25% in resource poor settings, suggesting a potentially high burden of disease that likely exacerbates an already precarious problem of malnutrition. The survey further showed a strong link between morbidity and malnutrition, with 75% and 82% of acutely moderate and severe malnourished children, respectively, reportedly sick in the 14 days prior to the study. Similarly, the prevalence of malnutrition amongst those children who reported an illness in the previous 14 days was 23%, compared to 7% among non sick children (P<0.001).

In Uganda, a chronic existence of malnutrition is linked to chronic food insecurity and under-developed health services due to chronic and structural factors (understaffing, lack of resources, poor supportive infrastructure, etc.) and the consequences of the ongoing chronic conflict.

The results of the Uganda CFSVA 2009 indicates that 6.3% of households are food insecure, 21.3% are moderately food insecure and at risk of becoming food insecure if conditions deteriorate. The remaining 72.4% of the households are classified as food secure. The highest prevalence of food insecurity is in the region of Karamoja (20%), especially in the southern part of the region: Moroto (30%) and Nakapiripirit (23%).

In the region of Karamoja, approximately 208,000 people are estimated to be food insecure and 387,000 people are deemed to be moderately food insecure (total 595,000 persons). Given the acute nature of food insecurity, this region should remain a priority for future food security and nutrition interventions. In Karamoja, the high level of poverty, combined with recurrent shocks, are likely to be the main driving factors of food insecurity.

From the UNHS 2005/06, the estimate of acute malnutrition in the rural population was 6.1% global acute malnutrition and 1.9% severe acute malnutrition. Wasting was shown to be particularly high in the Karamoja part of the northern region. Approximately 17% of children were underweight and 4% of these were severely underweight. Stunting is estimated to be 39% (moderately or severely stunted) and 16% severely stunted in the rural population, being particularly high in the Southwest region [35].

The results of the nutritional survey conducted by Action Against Hunger (AAH) in December 2009 indicates 9.5% of Global acute malnutrition in Karamoja region and 6% in Kaabong district (WFH <-2zscore and/or oedema in Karamoja region), while 1.8% of severe acute malnutrition in Karamoja region and 0.6% in Kaabong
Study Protocol December, 2010

district (WFH < -3zscore and/or oedema [36].

Last nutritional survey conducted in May 2010 by ACF/UNICEF in Karamoja region, shows that Global Acute Malnutrition in the region increased from 9.5% (7.8%-11.2%) to 11.8% (9.6%-13.9%) between December 2009 and May 2010. Severe Acute Malnutrition remained at 1.8% [41].

MSF Spain has been in Uganda since 2005, undertaken successful medical programmes in various districts responding to emergencies and providing longer term support.

In Kaabong district began with a nutritional intervention in July 2007 after an alarming nutritional data in Kaabong district: Nutritional survey conducted in Kaabong district by MSF Spain, using WHO 2006 new standards, 19% of Global acute malnutrition (WFH < -2zscore and/or oedema in Karamoja region) and 3.4% of severe acute malnutrition (WFH < -3zscore and/or oedema), nutritional activities were handed over to Action Against Hunger at the end of 2008. Currently, activities are in the Paediatric ward in the hospital, ANC, Deliveries, PNC and covering remote areas with Mobile Clinics.

In June 2009 MSF Spain handed over activities in Lalogi Health Centre IV programme and this location is now regarded as the template health centre for Gulu district. Related to this project and in conjunction with the London School of Hygiene & Tropical Medicine and the Gulu University, MSF Spain facilitated the study “The women we never see: Potential strategies to increase women’s use of labour and delivery services in northern Uganda”. Currently MSF Spain is, by agreement, supporting the BL6 unit in Uganda for the clinical trial “Assessing Three Day Pentamidine treatment for First Stage Human African Trypanosomiasis in Uganda” (Ugandan protocol number: Study No: HAT PDE 06-02).

In Karamoja region and in collaboration with the local and State Ministry of Health, Médecins Sans Frontières will carry out the operational research in a MoH OPD located in Kaabong Hospital where MSF will provide support in diagnoses and treatment. In 2009, there were 13,086 clinical visits for children under 5, of which 13% (1697) included a malaria diagnosis, 19.7% (2578) diarrhoea and 21.5% LRTI (2816). Although MSF is not in charge to treating acute malnutrition, all the cases detected in the OPD are referred to AAH (Action against hunger). In 2009, were referred 655 cases (5%) of moderate acute malnutrition and 318 cases (2.4%) of severe acute malnutrition.

In Karamoja region and in collaboration with the local government and State Ministry of Health, Médecins Sans Frontières Spain will carry out the operational research in a MoH OPD located in Kaabong Hospital (Kaabong district) where MSF will provide support in diagnoses and treatment. The aim of this operational research is to assess whether nutritional supplementation will significantly reduce both, the incidence of malnutrition and the incidence of the three main childhood illnesses. If successful, this may prevent subsequent illness and break the vicious cycle of dependence between malnutrition and disease.

1.2 The inter-relationship between infection and malnutrition

The cause of malnutrition in most tropical countries is multi-factorial, involving not only an inadequate diet but also recurrent infections [2, 3]. Infections can lead to both anorexia and increased nutritional needs for recovery. These competing needs often lead to weight loss. Work by Rowland et al., for example, showed that amongst children 6-36 months of age, diarrhoea and malaria contributed to a mean weight loss of 746 grams and 1072 grams per episode, respectively [4].

Failure to return to normal nutritional status after an illness increases a child’s susceptibility to further infections, perpetuating a cycle towards further reduced nutritional state [4-7]. When inadequate nutrition limits recovery, there is increased risk of a permanently lowered nutritional status [8].

However, there are reports that acute weight loss during episodes of acute infection can be mitigated by good nutrition. [9, 10]

A work done in Karamoja by S.Gray et al, say that weight loss of Karimojong children in the third year corresponds with the timing of weaning. Mothers wean children relatively abruptly in some cases (pregnancy, work, etc) while responsibility is transferred to older siblings or elderly women, too old and weak to accommodate the physical demands of causal labor or food foraging. Weaning in Karamoja population is associated with a decline in nutrient quality of children’s diet and acute psychological as well as physiologic stress (elimination of

\[^\text{Nutrition Surveillance in Karamoja Region. ACF/UNICEF, May 2010.}\]
\[^\text{MSF-OCBA nutritional and retrospective mortality survey in Kaabong district, Karamoja region, Uganda, November 2007.}\]
\[^\text{Until Mach 2010 MSF was supporting the MoH structure with on the job training for MoH staff.}\]
\[^\text{Until Mach 2010 MSF was supporting the MoH structure with on the job training for MoH staff.}\]
milk from the diet, termination of breastfeeding expressed as anorexia in some children), compromising their nutritional status an increasing susceptibility to infection [39].

"In HIV patients, the prevalence of malnutrition in sub-Saharan Africa is influenced by a host of factors, which includes seasonal variation, droughts and floods, the prevalence of infectious and chronic diseases, variable sanitary conditions, and social and political events. Survey estimates of clinical malnutrition are complicated by large and dispersed rural populations, a lack of appropriate diagnostic modalities, and potential confounders of associated signs and symptoms (eg, weight loss, edema, and physical manifestations of vitamin and mineral deficiencies)” [38].

Infants HIV infected and HIV exposed but un-infected, have an elevated mortality risk compared with infants born to mothers who are HIV negative. The reasons behind this increased mortality risk in uninfected, but exposed infants are not well understood. It is thought that a combination of immune compromise and nutritional deficiencies are implicated [37]. For the first 6 months infants are fed exclusively or predominantly by breast; at 6 months of age complementary foods are introduced. A complementary food is any food given in addition to breast milk. Complementary foods should provide a varied diet: fruits, vegetables, cereals as well as some egg, meat or fish (animal-sourced foods) to cover vitamin and mineral deficiencies.

Taking into account MSF experience treating acute malnutrition in HIV infected patients, weight loss can be as well the consequence of different process or of the lack of food at home for covering their nutritional needs. Patients HIV infected can recover their nutritional status with appropriate treatments in case of acute malnutrition. Lack of response may be a problem with the treatment or the presence of other untreated condition (as for example, malabsorption, bad control of opportunistic infections).

1.3 Effect of supplementation

1.3.1 Supplementation to prevent malnutrition

In order to prevent malnutrition after an infection, the World Health Organisation (WHO) recommends that caretakers give children one additional healthy meal daily during the two weeks after the onset of illness. [11] In resource poor settings this strategy is likely to be inappropriate, as caregivers often lack resources, including healthy ingredients, to implement this recommendation. Therefore, a more effective strategy in resource poor areas may be to provide an ill child with a nutritional supplement. One option would be to provide this supplement at point of care.

“The control of vitamin and mineral deficiencies is an essential part of the overall effort to fight hunger and malnutrition. Countries need to adopt and support a comprehensive approach that addresses the causes of malnutrition and the often associated “hidden hunger” which rest intrinsic to in poverty and unsustainable livelihoods.

… among other options that are aimed at increasing the intake of micronutrients, programmes that deliver micronutrient supplements often provide the fastest improvement in the micronutrient status of individuals or targeted population groups.” [40].

Meta-analyses also report the significant positive effect of multi-micronutrient supplementation on child weight, using pooled data from interventions with a duration ranging from 8 to 52 weeks [12].

Supplementation amongst ill children could also result in improved weight gain. Weight loss during infections is caused primarily by anorexia. Micronutrients play an important role in the regulation of anorexia. An infection can induce secondary micronutrients shortages and a shortage of some micronutrients might cause anorexia to persist over time.

Therefore supplementation of multi-micronutrients might mitigate weight loss in sick children, though evidence is scarce. One study, in The Gambia, showed that weight loss amongst children with acute diarrhoea was significantly lower when provided a supplement enriched with vitamins and minerals for 2 weeks after diagnosis, compared to a control group with diarrhoea but no supplement. [10]

1.3.2 Supplementation and reduced risk of disease

The effect of supplementation in the vicious cycle of malnutrition and diseases could be two fold: reducing weight loss during illness and reducing the frequency of illness.
Several micronutrients have been proven to reduce the severity and frequency of illness. Studies have shown that zinc supplementation during diarrhoea reduces the severity and frequency of both diarrhoea and lower respiratory tract infections.[13] Vitamin A supplementation has been shown to reduce mortality in general. [14]

In the fore mentioned DRC study [15], those receiving supplementation were significantly less likely to report cough at 14 days after beginning the supplementation (AOR: 2.85, P=0.005), suggesting disease can be reduced with supplementation.

1.4 Supplements

Micronutrients can be delivered in a number of forms, including pastes (including energy and proteins) or powders.

1.4.1 Ready to Use Therapeutic Food

Ready to Use Therapeutic Food (RUTF), is a paste and packaged in individual portions that can be eaten directly from the package without additional handling or preparation. There are several brands of RUTF currently available and widely used (e.g. by UNICEF), including Plumpynut® and Eezeepaste®. It is designed for catch up growth in malnourished children [16-18] and mass distribution resulted in prevention of malnutrition. [19] Therefore RUTF can be expected to promote weight gain after a period of weight loss due to infection.

In the Democratic Republic of Congo (DRC) van der Kam et al. studied potential benefits on weight gain after providing RUTF to children 6-59 months of age with a confirmed malaria infection. Children were randomised to receive either 14 days of a RUTF or to receive no nutritional intervention. Results showed that though the intervention group had a significantly greater mean weight gain during the first 14 days (P=0.005). Both groups showed a similar mean weight gain at 28 days of follow-up that can be contributed to the relatively stable food security situation in the study area allowing for catch up growth. [15]

The faster recovery in the supplementation group could be more relevant in food insecure areas with a high disease burden.

1.4.2 Multi-Micronutrient powder

The WHO, WFP and UNICEF specify a recommended micronutrient composition as a supplement for healthy children. When fortified rations are not available, children aged 6 to 59 months should be given a daily dose of the micronutrient supplement (See Annex 11 composition Mixme and Plumpynut). [20].

Multi-micronutrients can be delivered in the form of a powder. The micronutrient powder (MNP) is tasteless, colourless and are spread over or mixed with a meal prior to consumption. MNPs are packed in very small sachets that contain a quantity appropriate for one meal for one person. Advantages of MNPs include being highly portable (MNPs do not include macronutrients) and their acceptability. The latter is especially important for children who usually show a low acceptability and compliance for tablets. There are two key brands of MNP currently available and widely used (e.g. by WFP and UNICEF), including MixMe® and Sprinkles®. Both are well tolerated by children and caregivers and are easy to administer resulting in a high compliance. In Bangladesh, compliance is reportedly 80-85%. [21, 22] MNP’s have shown to be successful in treating and preventing anaemia. [23, 24]

1.5 Rationale for the study

MSF works throughout the world providing essential medical care through basic health care services, including nutritional feeding programmes and OPD clinics. Given the endemicity and magnitude of illnesses in sub-Saharan Africa, this study aims to explore the effectiveness of nutritional supplementation concurrently with an episode of one of the three key morbidities (malaria, diarrhoea and LRTI) in reducing incidence of malnutrition and recurrence of these three morbidities. If shown to be effective, MSF would consider incorporating nutritional support in its OPD protocols as supportive therapy for these infections and as a routine component of the strategy in preventing malnutrition and recurrent infection. The interventions studied are also felt to have wider relevance outside of MSF, and if results are positive, MSF will advocate to Ministries of Health, WHO and donors to include the intervention in their basic package of care.

To date there has been no evidence to show the impact of nutritional supplementation on incidence of malnutrition or morbidities amongst routine users of OPD services. In addition, there is limited information on how to roll out such an intervention, including which populations to target, the composition suitable for ill children and the preferred form of delivering such supplements.

Though RUTF is a standard fortified food product seen in many MSF interventions, it is a logistically heavy product (i.e. cost, bulk and weight). The question remains as to whether it is essential to include the macronutrient...
components (incl. energy and proteins) of RUTF. It is not evident that macronutrients are necessary to prevent malnutrition in children with disease, as anorexia is modulated by micronutrients. It is important from a cost effectiveness perspective to investigate whether micronutrients alone would prevent malnutrition in ill children. For this reason, two commonly used supplements will be investigated, i.) an RUTF with both macro- and micro-nutrients and ii.) a powder with only the multi-micronutrient component.

The duration of the supplementation should cover the period to recover from weight loss and disease. A study from Gambia suggests that recovery from weight loss for diarrhoea occurs within the first 14 days [10]. In addition, 14 days will cover convalescence from disease. Finally 14 days is an operationally feasible intervention.

While timely and appropriate treatment of disease is the priority, a nutritional supplement for a short duration (14 days) as a complimentary therapy might have an impact on the incidence of illnesses. The aim of this study is to assess whether nutritional supplementation will significantly reduce both the incidence of malnutrition and the incidence of the three main childhood illnesses. If successful, this may prevent subsequent illness and break the vicious cycle of dependence between malnutrition and disease.
2. STUDY OBJECTIVES

The aim of the study is to “To determine the effectiveness of 14 days nutritional supplementation (RUTF or MNP) given concurrently with the appropriate medical treatment, in children diagnosed with malaria and/or diarrhea and/or LRTI in reducing the incidence of acute malnutrition and the incidence of the three study diseases compared to a control group.”

The primary objective is to determine the effectiveness of 14 days of RUTF supplementation versus no supplementation control group on the incidence of acute malnutrition.

Primary Hypothesis: Supplement for 14 days with RUTF, concurrent to appropriate medical treatment for malaria, and/or LRTI, and/or diarrhea reduces the incidence of acute malnutrition compared to a control group during 6 months follow-up, amongst children 6-59 months of age with malaria and/or, LRTI and/or diarrhea at time of recruitment.

Secondary objectives include:

Incidence of malnutrition
i.) Determine the efficacy of 14 days MNP supplementation versus a control group and RUTF versus MNP on the incidence of acute malnutrition during 6 months follow-up,

Frequency of morbidity
ii.) Determine the effect of 14 days supplementation on the frequency of morbidity (3 study diseases) during 6 months follow-up, comparing both intervention groups to the control group and comparing RUTF to MNP

Weight changes immediately after intervention period, measured at day-14 and day-28
iii.) Measure mean weight change (total change and rate (grams/kg/day) of change), comparing both intervention groups separately (RUTF and MNP) to control group
iv.) Determine frequency of ‘no weight gain and/or weight loss’, comparing both intervention groups separately (RUTF and MNP) to control group
v.) Assess if provision of 14 days of RUTF or MNP supplement promotes a sustained weight gain, measured after 28-days of follow-up, comparing both intervention groups separately (RUTF and MNP) to control group

Sub group analyses
vi.) Children under 3 years of age at inclusion: Determine the effect of 14 days supplementation on the incidence of acute malnutrition and frequency of morbidity (3 study diseases) during 6-months follow-up, comparing children under 3 years of age to older children.

vii.) Breastfed children: Determine the effect of 14 days supplementation on the incidence of acute malnutrition and mean weight gain (incl. rate) during 6-months follow-up, comparing breastfed children to those not breastfed.
3. STUDY DESIGN

This is a randomized controlled trial with three study groups. Children 6 to 59 months of age presenting at the OPD in Kaabong Hospital Kaabong district, Karamoja region and diagnosed with one or more of the three study diseases (malaria, diarrhoea and LRTI) are eligible for the study.

Children participating in this study will be randomised to one of the three groups to:
A) Receive 14 days of RUTF supplementation with standard care and treatment or
B) 14 days MNP supplementation with standard care and treatment
C) Be included in a control group receiving standard care and treatment but not receiving nutritional supplementation (control group)

Individual follow-up will be 6 months. During this time, children in the RUTF or MNP group will receive 14 days nutritional supplement every time diagnosed with at least one of the three study diseases, not exceeding more than 14 days supplementation in any 28 day period.

4. STUDY SITE

The study site is a MoH/MSF Paediatric OPD located in Kaabong Hospital. Karamoja, Uganda, where MSF will provide support in diagnoses and treatment. This site was selected among other MSF programmes taking into account different factors: pastoral and agricultural population, food security, food consumption, diet composition, food sources and high incidence of diseases such as malaria, diarrhoea and LRTI [35]. The aim of the study is to assess whether nutritional supplementation will significantly reduce both, the incidence of malnutrition and the incidence of the three main childhood illnesses. If successful, this may prevent subsequent illness and break the vicious cycle of dependence between malnutrition and disease.

4.1 Number of Participants

The total study population will consist of 2,202 participants, 734 per study group. All children will be recruited at one study clinic site. The study team is expected to recruit approximately 15 participants per day, requiring approximately 143 working days (approximately 29 weeks based on a 5-day work week) for recruitment.

4.2 Inclusion criteria

Children will be included if they meet all the following inclusion criteria:
- 6 to 59 months of age
- Not malnourished children
- Diagnosis of malaria and/or diarrhoea and/or LRTI
- Intending to remain in area for the duration of the 6 month follow-up
- Living within approximately 60 minutes walking distance from the clinic
- Informed consent from a guardian*

* Parent or other legal guardian. If not a parent, must be at least 18 years of age

4.3 Exclusion criteria

Children will not be included if they meet any one of the following exclusion criteria:
- Child is exclusively breastfeeding
- Child is acute malnourished
- Presence of ‘General Danger Signs’
- Presence of severe disease (including severe malaria, severe LRTI, severe diarrhoea)
- Needing hospitalisation for any reason
- Known history of allergy to the nutritional supplementation
- Having a sibling enrolled in the study*

* Until Mach 2010 MSF was supporting the MoH structure with on the job training for MoH staff.
† Information on the determination of the sample size is elaborated in section 9.1
Study Protocol December, 2010

*When one twin child is recruited, the twin sibling cannot be recruited but will receive the same supplement. This is done to limit the risk that, given the unique nature of twins, a guardian may share supplementation with twin siblings.

Patients who do not meet all eligibility requirements and/or who fulfil any one exclusion criteria at screening will be considered not eligible for participation (See Annex f1-screening form).

5. PARTICIPANT SELECTION AND ENROLMENT

5.1 Identifying participants

Study patients will be recruited from amongst routine users of the Kaabong OPD services. Initial diagnosis of the study diseases will be conducted at the Paediatric OPD using MoH/MSF clinical diagnostic tools and protocols.

Patients diagnosed with one of the 3 study diseases at the OPD will receive drug prescriptions as needed, a brief explanation about the study, and be voluntarily referred to the study clinic for further screening for study inclusion.

5.2 Consenting participants

Guardians of the participants will be informed about the purpose of the study, the procedures involved when participating, and asked for their consent. The parent or guardian of the child must be older than 18 years of age to give consent.

Informed consent forms will be translated into local languages, back-translated and piloted for comprehension in the area of the study site. As a significant proportion of the population is not literate, the consent form will be read out to the patient’s guardian to obtain oral consent as required (see annex f2-informed consent). Participants will receive a copy of the consent form for their reference.

It will be explained to the guardian that participation is voluntary and that patients will receive the same standard of medical treatment whether or not they agree to participate in the study. It will be further explained that patients can discontinue participation from the study at any time without explanation and without any negative impact on their future care and treatment.

5.3 Screening for eligibility

After referral to the study clinic, patients will be further informed about the study and screened by the study team.

A maximum daily number of children accepted for study screening will be defined according to the capacity of the study team. Based on information of how many OPD referrals the study team can expect per day, children referred will be selected systematically for further screening. As an example, if the study team can screen at most 30 children per day and they expect that 60 children will be referred to the study clinic from the OPD, every 2nd child will be screened for study inclusion. Selection for screening will be in the order of presentation to study clinic after referral from the OPD.

If the child is deemed eligible for the study according to inclusion and exclusion criteria, the guardian will be asked to voluntarily participate.

5.4 Ineligible and non-recruited participants

With limited screening capacity and a high volume of OPD patients with at least one of the study diseases, some children referred from the OPD to the study clinic will not be screened. If a child is not to be screened, the guardian will be informed of this immediately and be referred back to the MoH OPD to attain follow-up care or medications as per normal OPD protocol. This child will receive no further services from the study clinic.

6. RANDOMISATION

6.1 Randomisation

Simple randomisation will be implemented. There will be no reference to assigned study groups (e.g. no use of terminology such as group A, B, or C). Rather, the total patient numbers will be randomly allocated to an equal proportion of one of the three groups.

The randomization list will be computer generated by a statistician.
6.2 Blinding

Owing to the nature of the product packaging and use of a control group without placebo study participants will not be blinded to which study group they were assigned. It will also not be possible to blind staff distributing the supplement.

Study staff blinded to the allocation treatment includes:

- Principle investigator
- Co-investigators
- Field Research Coordinator
- All clinical and ancillary medical staff
- Technical staff collecting anthropometric measurements
- Questionnaire interviewers
- Data managers
- Statisticians

Every effort will be made to ensure that study staff remains blinded to the treatment allocation. Efforts will be made to inform participants and staff to avoid discussion that might reveal allocation.

The allocation scheme will be formally revealed only after the data from the last participant has been captured.

Each participant will be assigned a unique study identification number, used to identify the study participant in all procedures. Study numbers will be assigned sequentially as subjects enter the study. Once a number has been assigned, that number will not be used again (e.g. if a subject discontinues or a number is allocated incorrectly).

6.3 Treatment allocation

The study dispenser* will have access to a register with all unique study numbers and the assigned intervention. The study dispenser will allocate the study group to the participant when the participant collects the nutritional supplement. As such, the dispenser will be the only person of the study team to know the allocation scheme. The allocation register will be kept by the dispenser in such a manner that guarantees no unauthorized staff can have access. (see annex f9-dispensary allocation register)

7. NUTRITIONAL SUPPLEMENTATION

Guardians will be instructed in proper storage and consumption of the allocated nutritional supplement products. Refer to Annex 11 for the composition of these products.

7.1 RUTF (Plumpynut®)

Participants allocated to receive Plumpynut® will receive 14 sachets, one for each day. One package of Plumpynut® provides 500 kcal and vitamins and minerals, including vitamin A, B, C, selenium, zinc, folic acid, copper, iron. Ingredients used for the manufacturing of Plumpynut® include peanuts and milk components. (see annex 1)

7.2 MNP (MixMe®)

The MNP contains the micronutrients recommended by WHO, UNICEF, and the WFP (see Annex 11). In order to be approximately comparable with the micronutrient composition of RUTF the daily quantity is doubled. Participants allocated to receive MixMe® will receive 28 sachets, two sachets for each day of supplementation.

7.3 Control group

For the purpose of this study, it is not practically feasible to design and manufacture a placebo for RUTF or the MNP. Children randomly assigned to the control group will receive equivalent care and follow-up as the children assigned to a study group receiving supplementation. The only difference is that they will not receive a nutritional supplement (current clinical practice does not include nutritional supplement).

*One nurse assistant will be selected as study dispenser/treatment allocation (always will be the same person)

The paragraph refers to randomization. It is only highlighting that no one except one individual will have access to the list in order to avoid anyone influencing the randomization of patients to treatment.
8. CLINICAL PROCEDURES AND METHODOLOGY

8.1 Study clinic procedures at day of inclusion (day-0)

After inclusion, study procedures on day-0 include:

- Baseline socio-demographic questionnaire with i) Socio-economic data (incl. education level of guardian, whether family is receiving food aid, average number of meals consumed prior to clinical visit, etc.) and ii) Demographics (name, age, address) (see annex f4- General questionnaire)
- Child health questionnaire, including breastfeeding practices, duration of illness prior to clinical visit
- Anthropometric measurements, including weight, height, and MUAC
- Medical examination, including fever, concomitant illnesses, bilateral oedema
- Laboratory exams: haemoglobin, if indicated
- Counselling on the importance of providing their child with an extra meal during the convalescence period

Treatment of study diseases: All children will receive standard care and treatment according to current MoH/MSF medical protocols. This includes provision of zinc supplement to children with diarrhoea according to WHO and MSF recommendations.

DOT: For any drugs prescribed by the MoH OPD clinician, participants will be responsible for retrieving these drugs from the MoH pharmacy, as per normal practices. The first dose of prescribed drugs will be taken in the presence of a study nurse.

In addition to the three study diseases, participants presenting to the study clinic for follow-up visits (scheduled and unscheduled) will be cared for by the study clinic for any illnesses not requiring lengthy or complicated follow-up. Children suspected to have a serious illness will be referred to the MoH OPD or other appropriate services.

8.2 Follow-up schedule

After inclusion, the guardian will be instructed to return to the study clinic whenever the child is ill unless an emergency dictates attendance at a closer medical facility. Study staff will visit the OPD waiting room for study participants that might be mistakenly waiting there instead of going to the study clinic. MoH OPD will be asked to immediately refer all study participants to the adjacent study clinic.

In order to record any diagnoses and treatments prescribed when visiting a non-study clinic (i.e. private clinic, traditional healer, etc), participants be given a ‘study card’ describing the nature of the study and the need for non-study clinical staff to record on the card any new clinical data and medications provided or prescribed. Participants will be asked to actively provide this study card whenever consulting a non-study clinic. The decision to record diagnoses from a non-study clinic for study purposes will be made on individual basis, considering reliability and relevance of diagnosis (See annex f6 for the Patient Take-Home Card).

A number of procedures will be repeated during the follow-up visits at the study clinic. Patients will have a follow-up form for procedures to be ticked off when completed (see annex f3 - Study Follow-up Form).

Table 1 below gives an overview over all study procedures.

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Day 0</th>
<th>Day 14</th>
<th>Day 28 and every 4 weeks after</th>
<th>Unscheduled visits</th>
<th>Final visit (day 168)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Informed consent</td>
<td>✓</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Randomisation</td>
<td>✓</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Baseline questionnaire</td>
<td>✓</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Child health, history</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Clinical examination*</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Follow-up questionnaire</td>
<td>-</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>✓</td>
</tr>
<tr>
<td>Weight</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>✓</td>
</tr>
<tr>
<td>MUAC</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>✓</td>
</tr>
<tr>
<td>Height</td>
<td>✓</td>
<td>✓</td>
<td>-</td>
<td>-</td>
<td>✓</td>
</tr>
<tr>
<td>DOT</td>
<td>✓</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>RUTF / MNP distributed</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>
Compensation distributed

* Complete exam when diagnosed with an illness or otherwise deemed necessary, otherwise limited to a rapid exam, including assessing treatment side-effects and response

§ When indicated

**Questionnaires:** Questionnaires will be translated into local languages, back-translated and piloted for comprehension in the area of the study site. (See annex f4 for baseline questionnaire and annex f5 for follow-up questionnaire)

**Unscheduled visits:** If unscheduled visit occurs within 48 hours prior to a scheduled visit, the child will not need to return for that upcoming scheduled visit.

**Repeated supplementation:** Patients presenting with a new episode of a study disease will receive a new 14-day supplement, according to the intervention originally assigned. Though care and treatment will be available whenever ill, a child will not receive more than 14 days supplementation within any 28 day period. For example, a child receiving a new supplementation package on day-42 due to a newly diagnosed study disease cannot receive another supplementation package before day-70.

One reason to limit the distribution to a monthly frequency is to minimize potential bias related to the likelihood that children receiving Plumpynut® (a product known and recognized by the community) may be more likely to come forward for an unscheduled visit with the intention to receive additional distribution of supplementation.

### 8.3 Measuring malnutrition

Weight, height, MUAC and bilateral oedema will be measured upon inclusion and every following visit (scheduled and unscheduled). The nutritional status will be assessed using the weight-for-Height index according the WHO 2006 growth standards, MUAC, and the presence of bilateral oedema.

Quality control will be ensured through: Training, Supervision and Evaluation, a guideline with standard procedures is added as annexe. Supervision will be done during all the study period and repeated training whenever be necessary for assuring good results.

#### 8.3.1 Weight

**Time of day:** Because the weight of an individual varies during the day, weight will be measured at the same time of day on each follow up visit. With patients being recruited throughout the day, enrolment in the study and the first weight measured will be at any time on day-0.

To limit intra-day variation in weight, efforts will be made to ensure follow-up visits are scheduled at the same time of the day throughout the 6 month study follow-up. A weighing within 3 hours on either side of the original weighing will be accepted. If a patient arrives outside this limit, the participant will be asked to return the next day within the proper time window.

**Weighing procedures:** Two weighing scales, both SECA model 835, a very precise electronic scale, will be used for small babies and toddlers sitting or standing on the scale. Below weights of 20 kg the scale has a precision of +/-20 grams and for heavier weights up to 50 kg a precision of +/-50 grams. To minimize inaccuracy due to a child's movement, great care will be taken to place the scale level and on a stable surface and every effort will be made to ensure that restless children are kept calm during the weighing procedure. Quality control measures will be taken to ensure scale accuracy and the scales will be checked daily by a constant weight of 10Kg.

The weighing will be done by the same team of two (three) persons throughout the study, monitored and supervised closely by the field research coordinator (FRC). All children will be weighed undressed and without jewellery or other ornaments. One person will perform the weighing (ensuring scale is correctly positioned, correctly calibrated, and assisting the guardian with placing the child on the scale). The weight will be taken when the child is relatively still. This same person will read out loud the weight measured. The second person will visually observe the weight on the digital scale to confirm that it has been correctly read out loud and the second person will verbally repeat the weight and record the confirmed result on the appropriate form.

#### 8.3.2 Height

In order to detect even small increases in the height of a child, height will be measured at day-0 and every monthly visit to the clinic. Two (three) persons will use a precision height board (infant-child-adult measuring board, aluminium, Promes). One person will read out loud the height measured and the second person will verbally repeat the height for confirmation and record the result on the appropriate form.
8.3.3 MUAC
MUAC will be measured using an standard MUAC tape at day 0 and at the monthly visits. One person will read out loud the MUAC measurement and the second person will verbally repeat the measurement and record the result on the appropriate form.

8.3.4 Oedemas
Oedema will be evaluated by applying pressure with thumb to top part of the foot for three seconds. If an oedema exists, an imprint will be left on the part of the foot where pressure was applied. The oedema must be observed on both feet, legs or could be generalised (always bilateral oedema) for considering the child has nutritional oedema. Oedema will be evaluated at day 0 and at monthly visits.

8.4 Three study diseases
Three diseases/morbidities are targeted during this study: malaria, diarrhoea, and LRTI. Clinical diagnoses will be made using existing standard MSF/WHO protocols and case definitions [26,27] and a flow chart with step by step guidance and inclusion is detailed in Annex f7-diagnostics.doc.

- Diarrhoea:
The forms of diarrhoea include:
  1. Acute diarrhoea, simple without blood: the passage of at least three liquid stools per day for less than 2 weeks
  2. Persistent/chronic diarrhoea: diarrhoea beginning at least 14 days ago, and any period without diarrhoea has not exceeded two days. (WHO definition) [28]
  3. Bloody diarrhoea

- Lower Respiratory Tract Infection (LRTI)
  Refers to acute pneumonia:
    - children presenting with cough or difficulty breathing plus one of the following
    - Increased respiratory rate
      - Age 6–11 months: RR > 50 breaths /minute
      - Age 12 to 59 months: RR > 40 breaths /minute

- Malaria, Plasmodium falciparum and other species
  - Fever or history of fever within 24 hours with positive malaria RDT result

8.5 Compliance
Compliance regarding the consumption and acceptability of the nutritional supplements will be assessed only after the first 14 days of supplementation, through a questionnaire and collection of returned supplement sachets (used or unopened). The study dispenser will count and record the returned sachets (empty or unopened) after the questionnaire is completed.

8.6 Emergency unblinding procedures
Only when a serious adverse event occurs and it is deemed necessary to unblind a patient’s intervention group will that patient’s allocation be revealed.

8.7 Withdrawal procedures
Children will be withdrawn from the study if:
  i.) Participant fulfils criteria for acute malnutrition during follow-up period.
  ii.) There is a serious protocol violation
  iii.) Participant is erroneously included
  iv.) There is the risk that the nutritional supplement would negatively influence a prescribed medical protocol (i.e. medical treatment has priority).

Patients who become acute malnourished will be referred to MoH/Action Against Hunger (AAH) Supplementary and Therapeutic Feeding Program for care and treatment.

Participants who are withdrawn from the study will continue to be followed up if possible and monitored following standard study protocol. The use of data for analysis from withdrawn participants will be assessed by the study statistician.
8.8 Endpoints

8.8.1 Primary endpoint
The primary endpoint is “negative nutritional outcome (NNO)” of a child within the 6 months follow-up period. The incidence of a negative nutritional outcome will be defined according to the baseline nutritional status.

i) for children with no malnourishment at time of entry into study, “negative nutritional outcome” is defined as progression to moderate or severe malnourishment

Thus, the event of a child reaching a “negative nutritional outcome” at least once within 6 months of follow-up period will be compared between the three study groups.

8.8.2 Secondary endpoints
Secondary endpoints include:

- Number of NNO’s per study group in a period of 6 months
- Time to NNO
- Number of new events of a study disease in 6 months
- Weight change at 14 days and 28 days after study inclusion, and at end of study period
- Rate of weight change (grams/kg/day) at 14 days and 28 days after study inclusion, and at end of study period
- Proportion of children not gaining weight (including losing weight), measured at day-14 and day-28 after study inclusion.
- Proportion of children developing bilateral oedema
- Mortality: overall mortality, including the three study diseases and malnutrition.
- Morbidity, including the three diseases.
- Proportion of children with a reported cough at clinical visit

8.9 Data collection
An overview of forms where data are recorded is given in annex f10-overview data flow. Data will be routinely captured using EpiData software program, including double data entry to ensure quality data capturing.

Data will be routinely sent to the MSF Study PI and epidemiologist based in Barcelona for routine quality control. To minimise missing data during the trial, the database will be checked routinely. Any critical data missing will be obtained by questioning staff and, if necessary, the guardian.

Minimize bias must be done through training and supervision. Staff during all the study will be selected for the same responsibilities.

In an effort to minimise missing data, participants will be reminded of their scheduled visit 24 hours prior to the scheduled visit by means of mobile telephone. If a patient misses an appointment, the participant will be traced by outreach workers to ensure follow-up. When possible, information on the reason for missing data will be recorded.

Study data will be kept on the study site and handled confidentially. After study completion, all records will be stored in an appropriate manner at MSF offices at capital level for long-term storage. All data (paper records and electronic data) will remain the property of MSF-OCBA, who will commit to retain the data for 5 years.

MoH OPD patient medical cards will remain the property of the patient and/or health facility, as per current standard procedures in the routine health services.

9. DATA ANALYSIS
9.1 Sample size*

The sample size is based on the primary hypothesis: Supplementation for 14 days with RUTF, concurrent to appropriate medical treatment for malaria, and/or LRTI, and/or diarrhoea reduces the incidence of malnutrition.

The sample size calculation is based on a combined incidence of moderate and severe malnutrition amongst children who are sick.

There are hardly studies reporting the incidence of malnutrition and no studies reporting incidence of malnutrition among sick children. Therefore for the purpose of these calculations, we assume that the incidence is estimated by dividing the prevalence of malnutrition by the period of having malnutrition times 6 months: $\text{Incidence} = \left( \frac{\text{Prevalence}}{\text{Duration of moderate malnutrition}} \right) \times 6\text{ months}$

The estimated incidence for moderate and for severe malnutrition will be added to result in the incidence of negative outcome as defined as primary endpoint of this study.

The prevalence of moderate malnutrition among sick children is 15.5% and the prevalence of severely malnutrition among sick children is 7.2% according to the results if we take the survey done by MSF-OCA at February 2009.

Literature gives a duration of malnutrition (untreated) is estimated to be 7.5 months [29] and the duration of severe malnutrition is estimated at 4 months at the time of the survey. As duration of malnutrition might be different in the context of Karamoja we varied assumptions in order to use the lowest incidence as a basis for the sample size. This results in sample size that is large enough to give enough statistical power for the primary hypothesis (the sample size increases with a decreasing incidence). Increasing the prevalence of malnutrition in general or decreasing the duration of severe malnutrition (as there is treatment available) resulted in a higher incidence, but prolonging the duration of moderate malnutrition to 10 months gives a lower incidence.

Therefore the incidence is based on duration of 4 months for severe malnutrition and duration of 10 months for moderate malnutrition.

This results in an incidence of 0.201 per 6 months

Formula: $0.201 = \left( \frac{0.155}{10} + \frac{0.072}{4} \right) \times 6$

The assumed incidence rate in the control group (baseline incidence) is 0.20. A 30% reduction in the supplementation group, which is considered a clinically and operationally relevant improvement, results in an assumed incidence rate of 0.14 in each of the two interventions groups.

A Poisson regression with a binary independent group variable with proportion of 0.5 (equal allocation ratio) using a sample of 1320 observations (i.e. 660 per group) achieves 80% power at a 0.05 significance level to detect a incidence rate ratio of at least 0.7 (i.e. incidence rates of 0.14 (intervention rate) vs. 0.2 (baseline rate)).

To account for an assumed drop-out rate of approximately 10%, 734 children will be included in each group (i.e. 2202 in total for all three groups).

The sample size estimation is based on the first two hierarchical test hypotheses (while the third hypothesis comparing RUTF with MNP for non-inferiority is considered explorative). Sample size estimations are performed with PASS 2008 (Version 08.0.13, Windows XP) and SAS version 9.2 (SAS Institute, Cary, NC, USA).

9.2 Populations for analysis

Intention to treat population

The intention to treat population (ITT) includes all patients randomised that received at least one dose of study medication and who have baseline data recorded.

Per protocol Population

* In Karamoja OCBA project, acute malnutrition is not treated (it is in charge of AAH) and we cannot estimate the duration of moderate acute malnutrition and the prevalence of malnutrition among sick children for calculating the sample size. The sample size calculation has been determined extrapolating data from MSF-OCA.
The per protocol population (PP) includes all patients of the ITT population which were treated following the specifications of the study protocol without major protocol deviations. Excluded from the per protocol population will be patients that meet at least one of the following criteria:

- Violation of one of the following exclusion criteria: exclusive breastfeeding, hospitalisation for serious complicated illness (e.g. chronic illness).
- Not treated according to the allocated intervention group
- Patient misses more than 2 monthly scheduled visits
- Patient misses 2 or more consecutive monthly scheduled visits
- Participation in other feeding programmes

Completed the study
Patients will be considered as having ‘completed the study’ if they have attended at least the first and last scheduled visit at 6 months.

Baseline drop-out population
All patients who dropped out before the start of randomized treatment.

9.3 Descriptive Analyses
All available data will be analysed descriptively for each intervention group. Results will be summarised as frequencies and percentages for nominal data; as means, standard deviations, range, and 95% confidence intervals for continuous data; and as medians, quartiles, and ranges for ordinal data.

Differences regarding baseline variables will be analysed by appropriate tests (e.g. Chi squared test, Kruskal-Wallis test, or analyses of variance) in pair wise comparisons between the three treatment groups, and will additionally be checked for clinical relevance.

9.3.1 Primary analysis of the primary endpoint
The primary endpoint is “negative nutritional outcome” of a child within the 6 months follow-up period as defined in section 8.8.1. The incidence rate (in formulae below referred to simply as ‘rate’) of “negative nutritional outcome” will be computed as the number of events divided by total observed person-time in each treatment group. As an “event” the first time a child reaches a negative nutritional outcome will be used. The primary analysis of the primary endpoint will be performed on the intention to treat population with no imputation of missing data.

In the primary analysis, RUTF will be compared to the control group. The hypotheses in this step are

\[ H_0: \text{rate}_{\text{RUTF}} = \text{rate}_{\text{Control}} \]
\[ H_1: \text{rate}_{\text{RUTF}} \neq \text{rate}_{\text{Control}} \]

where \( \text{rate}_{\text{RUTF}} \) = rate of “negative nutritional outcome” in the children in the RUTF group, and \( \text{rate}_{\text{Control}} \) = rate of “negative nutritional outcome” in the children in the control group.

The comparison of rates among the treatment groups will be performed by a Poisson regression model, adjusted for nutritional status at enrolment (fixed effect) and will be performed within one model including the three intervention groups with contrasts for each two-group comparison. Tests will be two-sided with a significance level of 0.05.

9.3.2 Secondary analysis of the primary endpoint
Although the study is primarily powered for the comparison between the RUTF and control group the other groups will be compared as well, keeping in mind that the sample size might not be large enough to obtain significant results.

Since there are three interventional groups to be compared, a hierarchical test procedure will be used to account for multiplicity.

1) In a first step, RUTF will be compared to the control group, which is described above as analysis of primary outcome.

If the RUTF group is not significantly different at a 0.05 level (two-sided test), the hierarchical procedure is stopped (all following analyses will be considered explorative). If the RUTF group is significantly different at a 0.05 level, the hierarchical procedure is continued with step 2.
2) In the second step, MNP will be compared to the control group. The hypotheses in this step are

\[ H_0: \text{rate}_{\text{MNP}} = \text{rate}_{\text{Control}} \]

vs.

\[ H_1: \text{rate}_{\text{MNP}} \neq \text{rate}_{\text{Control}} \]

where rate\text{MNP}=rate of “negative nutritional outcome” in the children in the MNP group, and rate\text{Control}=rate of “negative nutritional outcome” in the children in the placebo to MNP group.

If the treatment factor is not significant at a 0.05 level (two-sided test), the hierarchical procedure is stopped (all following analyses will be considered explorative). If the treatment factor is significant at a 0.05 level, the hierarchical procedure is continued with step 3.

3) In the third step, RUTF will be compared to MNP (non-inferiority test). The hypotheses in this step are

\[ H_0: \text{rate}_{\text{RUTF}} - \text{rate}_{\text{MNP}} > -\delta \]

vs.

\[ H_1: \text{rate}_{\text{RUTF}} - \text{rate}_{\text{MNP}} \leq -\delta \]

where rate\text{RUTF}=rate of “negative nutritional outcome” in the children in the RUTF group, rate\text{MNP}=rate of “negative nutritional outcome” in the children in the MNP group, and \(\delta\)=non-inferiority margin.

As non-inferiority margin, a \(\delta\) of 2% will be used (i.e. allowing a slightly worse result in the MNP compared to the RUTF group). The third step will be tested at a 0.025 level (one-sided test), by a one-sided 97.5% confidence interval of the difference in rates between the RUTF and the MNP group.

In addition, in case of significant and/or relevant differences of baseline values additional adjustment(s) for these factors will be performed within the model described above (in models with and without interaction), to address the potentially confounding or effect modifying effect of other variables. These variables include age (in months and binary: <36 months, ≥36 months), gender, breastfeeding practices, cough, underlying illnesses, socio-economic factors, food availability, length of illness before visiting MSF clinic, other health support sought during study, season during which child was in the study.

The amount and pattern of missing data of the primary endpoint will be checked by a person blinded to treatment allocation, and a decision based upon the result of this check will be made as to whether and how the imputation of missing primary endpoint data will be performed.

Additionally, the 6-months follow-up period will be split and analysed separately for 1 month periods with the method described above.

The analysis of the primary endpoints will also be repeated as described above separately for children with no malnourishment at time of entry into study and children with moderate malnourishment at time of entry into study.

The analysis of the primary endpoint will be repeated as described above for the per protocol population.

9.3.3 Analyses of secondary endpoints

All secondary endpoints (as defined in section 8.8.2) will be compared between the three treatment groups as described above (p-values will be considered explorative). In addition to the Poisson regression model, logistic regression model, analysis of variance (ANOVA), analysis of covariance (ANOVA) and non-parametric analysis of variance will be used, according to the type of endpoint.

9.3.4 Pooled analysis

Prior to this study a similar study (pilot) had been conducted in Katanga, DRC, and a similar study will be conducted in Goronyo, Nigeria. After finalizing the studies the data from the three studies will be pooled and analysed jointly with adjustment for the study location.
9.3.5 Statistical analysis plan and software
A detailed statistical analysis plan (SAP) will be developed prior to the data analysis. Software used will be SAS for Windows, Version 9.2 or higher (SAS Institute, Cary, NC, USA) and STATA, Version 11 (StataCorp, College Station, Texas, USA).

10. QUALITY CONTROL

10.1 Coordination
A field research coordinator will be dedicated to ongoing supervision and monitoring of study implementation. Clinical procedures and data collection will be evaluated regularly by the FRC. Other QC measures will include daily review of patient records, observation of interviews and clinical procedures, and ongoing evaluation of malaria laboratory procedures according to standardised checklists.

The PI and OCBA epidemiologist will be present for the set up of the study site prior to implementation. They will also be available to conduct site visits every 3 months and make additional support visits as needed.

10.2 Diagnostics
Malaria RDT: Routine quality control procedures will include close monitoring and supervision of RDT performance against standardized monitoring checklists and blood films collected on a monthly basis including 15 positives and 15 negative samples to be crosschecked by expert microscopy as per the MSF OCBA quality control protocol.

P.Falciparum in Uganda has a prevalence superior 85% while P.Malariae, P.Ovale, P.Vivax prevalence is inferior 15%. If RDT result is negative but still clinic suspicion, diagnosis will be confirmed by laboratory to ensure that all the species are diagnosed.

10.3 Staff, Training, and Supervision
In addition to the FRC, the study will have a dedicated team, including medical doctor, nurses, study assistants (incl. collection of weight and height measurements, participant tracers, supplement dispenser, receptionist). Efforts will be made to identify and recruit and local staff.

Prior to study implementation, the PI and OCBA epidemiologist in collaboration with OCA epidemiologist and or investigator, and with the FRC, will provide initial training and support in study methodology and implementation. Targeted training will be provided for specific team roles and responsibilities, including clinical diagnostic algorithms, proper use of the malaria RDT, and technique in conducting objective questionnaire interviews, and accurate weight and height measurements.

To assure quality control, constant training, supervision and evaluation will be provided during all the study period for assuring good results.

In addition, staff will be briefed on the MSF ways of working, its role and mandate.

11. ETHICAL CONSIDERATIONS
The study will be performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with International Conference on Harmonisation (ICH)/Good Clinical Practice (GCP) and all applicable regulatory requirements.

11.1 Treatment of participants
Confidentiality
The medical examinations and the interviews will be performed in a private setting to ensure patient confidentiality. Patient data will only be accessible to the relevant clinical staff and not accessible to any unauthorized person. In further data processing, patient data will be pseudonymous, and identified only by the

\[\text{Centre for Disease Control and Prevention (CDC). http://www.cdc.gov/}\]

\[\text{A quality control sample in measurements is a standard procedure to repeating an x number of measurements, e.g. 10 children measured twice for weight, height and MUAC for finding mistakes doing the same measures with the same team. This type of training and evaluation is a standard practice. In surveys, it is included in the SMART programme giving the training results automatically.}\]
study number.

**Optimal medical treatment**

Patient management will be based at all times on their clinical condition, independent of participation in the study. Participation in the study will not, at anytime, preclude supplementary treatment or a change in therapy if clinically indicated. The well-being of the patient will always be prioritised over study participation. The study does not interfere with routine care normally delivered to children presenting to the Kaabong OPD. Children requiring hospitalisation on presentation will not be recruited into the study, children who are acutely malnourished; they will be referred to MoH/AAH programme.

**Burden on study participants:**

Individual study participants will be asked to attend for minimum 8 visits. A small compensation for time spent on travel and at the study clinic will be given after each scheduled clinical visit, e.g. a bar of soap. The incentives, or rather compensation (see annex f12 for incentive), are given after each visit to keep an interest of coming, to avoid suspicion that participation only cost only time and efforts. At the end of the study a larger compensation will be provided, e.g. blanket and salt. The total costs of the compensation will be equivalent to the market value of the approximate average duration of travel and time spend in the clinic for the research. This will be approximately 10 hours. Choices for the products will be made in close collaboration with a diversity of stakeholders within the community (mothers, community health workers, District Health Officer) and in observation of market prices.

**11.2 Cooperation with national and local partners**

Collaboration and cooperation between MSF-OCBA and Uganda health authorities is critical for the success of this study and uptake of results if positive outcomes are demonstrated. It will be essential to ensure access to and provision of study information to key policy in combating malnutrition. Permission to run the study will be obtained from the Uganda National Health Research Organisation (UNHRO). In addition, the local administrative authorities will be consulted about the nature and time-schedule of the planned study.

The details of the study and its implications will be discussed with all relevant stakeholders, at local and national levels. Dr James Kisambu, the Kaabong DHO, will be assigned co-authorship to assure that there is local dissemination of study progress, the study results to the local participating community. Also Dr James’ long term association with Kaabong aims to allow the study research to contribute to local research skill building.

As the study involves a temporary intervention with a temporary benefit for those receiving an active intervention, it is essential that community members understand the purpose of the investigation and agree with the procedures. MSF-OCBA field visitors will consult with village chiefs and community members, especially targeting women with young children throughout the study to ensure understanding and ongoing community acceptance of the study.

**11.3 Benefits to the community**

If shown to be effective, this would contribute to reducing morbidity and mortality amongst the children in the community. Based on the positive outcome of this study, MSF will adapt protocols to include provision of nutritional supplementation for children with serious acute illness. Assuming positive benefit of the intervention, MSF will advocate with the MoH, and with donors for provision of the supplement. While it is accepted that RUTF is an expensive intervention and may be difficult for the MoH to implement alone, previous MSF prevention studies for malnutrition have resulted in uptake of the RUTF distribution strategy by UNICEF and WFP. If the study shows MNP to be effective, we anticipate this to be an intervention that can be implemented with minimal cost impact. In addition, we would consider cost effectiveness studies if this was needed to convince decision-makers to implement the nutritional intervention.

The study also hopes to contribute to an improved understanding within the community, including medical staff, that good nutrition is essential after during and an acute infection.

Study participants will further benefit from monthly routine screening, intensified follow-up treatment and care.

Finally we want to address the issue of commercial interest. Plumpynut® is under patent protection currently. The Access to Medicines Campaign of MSF has been actively following this issue for the last years, and currently the patent is under pressure in a number of countries. More manufacturers are now producing RUTF, for example Compact produces a nutritionally equivalent product, called EeZeePaste® which is now used in some MSF programs. MixMe® is a product that as stated is widely used and similarly to another product on the market. It is
distributed by UNICEF through a donation from the manufacturing company. We therefore do not see any direct commercial interest accruing as a result of this study to either the makers of Plumpynut® or MixMe®.

11.4 Feedback of results
Individual child results will be shared and discussed with the guardian in such a manner to not jeopardize established blinding of the study interventions. At the end of the study, feedback and preliminary outcomes will be provided to the community and to medical authorities.

11.5 Potential risks
The potential risk due to a nutritional supplementation is very low. The supplementation products have a history of proven effectiveness and benefit in similar settings. Nonetheless, any intervention carries with it a certain level of risk and, as such, participants must be monitored closely.

A paper by Caulfield et al. [30] reviewed the relation between iron supplementation and risk of reduced malaria parasite clearance rates and increased risk of treatment failure. However, these studies have been criticised on several points, including the use of a malaria treatment (sulfadoxine - pyrimethamine) in an area with parasite resistance to these drug components. [31]

Caulfield et al. conclude that no consensus exists on the risks of malaria morbidity and mortality associated with iron supplementation and that the alleviation of anaemia through iron supplementation is likely to have a far greater net benefit for an iron-deficient population, including those in malaria-endemic regions. The WHO concludes that routine iron supplementation is prioritised even in malaria endemic regions. [32] A recent Cochrane review (2009) that includes the studies mentioned above in their review, concludes that iron does not increase the risk of clinical malaria or death, when regular malaria surveillance and treatment services are provided.[33]

11.6 Adverse events
An adverse event (AE) is any medical event affecting a clinical trial participant. For each adverse event should be evaluated whether this event is potentially directly related to the RUTF or MNP supplementation, e.g. vomiting, rash, sudden death after eating etc.; An adverse reaction (AR) is where it is suspected that an adverse event has been caused by a reaction to one of the supplements.

In this study the primary (incidence of malnutrition) and several secondary outcomes (e.g. frequency of disease) are per definition an adverse event but these will not be considered as an adverse reaction.

A serious adverse event /reaction
- results in death;
- is life threatening (i.e. the subject was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe);
- requires hospitalisation; (excluding a therapeutic feeding centre)
- results in persistent or significant disability or incapacity;

Participants will be instructed to contact the clinic if any medical condition develops. The study team will examine the patient and will contact the FRC when a serious adverse event or a suspected adverse reaction (serious or not) occurred. The FRC will report the information to the PI within 24–48 hours of becoming aware of the event. The FRC will initiate the appropriate care and treatment according to their medical judgment.

The report includes study group, type of event, onset date, investigator assessment of severity and causality, date of resolution as well as treatment required, investigations needed and outcome.(see annex F8-serious adverse event/reaction). Depending on severity, when an SAE / SAR occurs, the FRC will review all documentation (e.g. hospital notes, laboratory and diagnostic reports) related to the event. Alternative causes such as natural history of the underlying disease, concomitant therapy, other risk factors and the temporal relationship of the event to the supplementation will be considered.

A subgroup of the study advisory group (including the OCBA Medical Director, the Principal Investigator) will continuously review the occurrence of all serious adverse events and adverse reactions. On authority of the OCBA Medical Director or MoH of Karamoja the study can be interrupted altered or stopped as a result the investigation of adverse reactions (SAE or SAR).

11.7 Interim analysis and Data and Safety Monitoring Board
An interim analysis is not required in this study. The study sample size and the 6 month follow-up period is the minimum needed before having the statistical power to show evidence of any significant (operational or statistical) difference in the primary outcome (negative nutritional outcome; ‘NNO’) when comparing study groups.

In addition, occurrence of SAE’s, SAR’s and mortality will be monitored, evaluated and reported routinely throughout the study. A subgroup of the study advisory group (including the OCBA Medical Director, the Primary Investigator and Field Research Coordinator) will continuously review the occurrence of all SAEs and SARs. On authority of the OCBA Medical Director or the MoH of Kaabong, the study can be interrupted, altered or stopped as a result of these investigations. The MSF ERB and local ERB/MoH will be immediately informed if this is the case.

Due to the proven safety of the supplementation products and because the products are not used in a manner very different than that already proven safe, the use of an independent Data and Safety Monitoring Board (DSMB) is not warranted. If the advisory committee is unable to make a decision on the outcome of the interim analysis, an independent body external to MSF will be immediately consulted.

12. STUDY INVESTIGATORS AND THEIR ROLES

The Medical Department of MSF-OCBA is responsible for the study. Only on the authority of the Medical Director of MSFOCBA or the MoH of Uganda should the study be substantially altered or stopped. The principal investigator (PI), C. Roure Pujol, is accountable to MSF-OCBA. An advisory committee will advise the PI at crucial stages on design and implementation of the study and includes:

<table>
<thead>
<tr>
<th>Name</th>
<th>Title</th>
<th>Role</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salse Ubach, Núria</td>
<td>Principle Investigator</td>
<td>Responsible for the research including implementation and report writing. Guarding the OCBA budget. Represent the research internally and externally.</td>
<td>MSF-OCBA, Barcelona, Spain</td>
</tr>
<tr>
<td>Kam van der, Saskia</td>
<td>Investigator</td>
<td>Responsible protocol design; and for support for analysis of result and/or eventual support for writing final report.</td>
<td>MSFOCA, Amsterdam, The Netherlands</td>
</tr>
<tr>
<td>Swarthout, Todd</td>
<td>Epidemiologist</td>
<td>Contributing to study design, implementation and writing of protocols; guiding data management and advice on interpretation of results.</td>
<td>MSFOCA, Amsterdam, the Netherlands</td>
</tr>
<tr>
<td>Roddy, Paul</td>
<td>Epidemiologist</td>
<td>Contributing to implementation procedures; directly involved in the implementation of the research in the field; guiding data management and support writing final report.</td>
<td>MSFOCBA, Barcelona, Spain</td>
</tr>
<tr>
<td>Veronique De Clerck</td>
<td>Medical Coordinator, Uganda</td>
<td>Providing advice on issues related to local circumstances and overall organization of implementation of the study and responsible for all communications with the authorities concerning the study.</td>
<td>MSFOCBA, Kampala, Uganda</td>
</tr>
<tr>
<td>Akiko Matsumoto</td>
<td>Field Research Coordinator (FRC)</td>
<td>Responsible for hiring and training of staff, pilot protocol, organise implementation, ensuring the quality of diagnosis, treatment, procedures, the case reports, follow-up visits and data entry. Communicate directly with PI, Medco, epidemiologist when required.</td>
<td>MSFOCBA</td>
</tr>
<tr>
<td>Roll, Stephanie</td>
<td>Statistician</td>
<td>Responsible for sampling and statistical procedures, analysis, interpretation of results and formulation of recommendations. Advice on study design</td>
<td>Institute for Social medicine, Epidemiology and Health Economics Charité University</td>
</tr>
</tbody>
</table>
Authorship

The PI is responsible for drafting the report of this study, in collaboration with the OCBA and OCA epidemiologist or investigator. Publication in an appropriate medical scientific journal will be sought. The PI is responsible for ensuring the collaboration and consent of all co-workers and for submitting a draft version of the final report to the advisory committee within three months of completion of the study.

Authors will be drawn from the advisory committee and will be considered to be authors on 1) substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3.

Other members of the study group will be acknowledged as contributors in any publications or presentations.
13. REFERENCES


15. Kam, v.d.S.S., T; Niragira; O. Froud, A; Mukonema Sompwe, E;Mills, C; Shanks,L; Roll, S; Tinnemann, P., The effectiveness of ready-to-use therapeutic food (RUTF) for catch-up growth after an episode of P.falciparum malaria. planned, 2010.


21. WFP, D., UNHCR, Micronutrient Powder (MixMe™); Program for Under-fives and Pregnant and Lactating Women Affected by Cyclone Sidr in Bangladesh (Asia) 2009.


25. WHO, W., UNICEF, Preventing and controlling micronutrient deficiencies in populations affected by an emergency. Multiple vitamin and mineral supplements for pregnant and lactating women, and for


33. Ojukwu, J., et al., Oral iron supplementation for preventing or treating anaemia among children in malaria-endemic areas. status and date: Edited (no change to conclusions), published in, 2009. 4.

